Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, announced today the launch of its BaseCase Portal cloud-based platform, that allows for the rapid creation of fully-customizable mobile apps that connect live to mathematical models and algorithms, and help HCPs optimize treatment for individual patients.
By creating an intuitive front-end, BaseCase Portal enables clinicians to use complex scientific models and algorithms that were previously only available in research settings, to guide therapeutic decision-making.
For example, a company can now create an app that runs a mathematical model to generate a dosing recommendation based on individual patient characteristics, and deploy that app rapidly to the HCPs mobile device using BaseCase Portal.
Unique in the industry, Certara provides a full spectrum solution for creating precision dosing apps, by leveraging the companys expansive model-informed drug development, regulatory science, market access and real-world evidence solutions with BaseCase Portal technology.
With this new platform, Certara ushers in a new era of model-informed precision dosing at the point of care, said Thomas Kerbusch, PhD, president of Certara Strategic Consulting. In fact, Certara is bringing together its strategic drug development, modeling and simulation/pharmacometrics, market access, health economics/outcomes research, regulatory sciences, and interactive mobile app development together to create this user-friendly platform, thus strengthening how our clients deliver treatment to patients.
We are proud to report that BaseCase Portal has been well received and was already selected by both a top 10 medical technology and a top 10 pharma company prior to launch, Dr. Kerbusch added.
Our clients can now equip clinicians with scientific tools that were previously too complex to be used at the point of care. By wrapping complex algorithms into user-friendly apps, we can make use of a body of science that has been growing for decades but has been largely untapped to improve patient care. Its a very exciting time for us, said BaseCase Managing Director Gijs Hubben, PhD. The next step for us is to extend BaseCase Portal to allow for the integration of web-apps into the hospital EMR, so that patient data can be efficiently shared without the need for separate data entry.
Founded in 2007, and acquired by Certara in January 2018, BaseCase is a software as a service (SaaS) and value communication company that has been developing interactive mobile apps for the pharmaceutical and medical device industries for more than a decade.
BaseCase Portal keeps a strict separation between the user interface, and the underlying mathematical model. This offers many benefits over the old way of doing things in which algorithms typically were hardwired into a website. On BaseCase Portal, algorithms and models can be validated and updated much more easily. Furthermore, BaseCase Portal features embedded version control and release workflows, and provides an audit trail, allowing a new version of an app to be uploaded as soon as it receives the requisite legal and regulatory approvals. Synchrogenix, Certaras regulatory science business, can also assist clients with filing the full range of global submissions.
Via a self-service sign-on process, BaseCase Portal provides healthcare providers with rapid access to fully-compliant mobile apps. The apps can be accessed either online or offline via iPad or iPhone. A key component of the Portal is the ability to release a package of different language versions of apps, which have been translated and labelled by region and therapeutic area, to facilitate the roll-out of apps across multiple markets.
Besides precision dosing apps, BaseCase Portal can also be used for diverse purposes such as providing education and facilitating collaboration. Examples include apps that provide product information, inform on guidelines and treatment pathways, and track the progress of global studies.
As BaseCase Portal is a white label solution, it can be tailored to reflect each clients brand identity.
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. As a result, it optimizes R&D productivity, commercial value and patient outcomes. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. For more information, visit www.certara.com.